TIVICAY PD's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
Tivicay Pd is owned by Viiv Hlthcare.
Tivicay Pd contains Dolutegravir Sodium.
Tivicay Pd has a total of 4 drug patents out of which 0 drug patents have expired.
Tivicay Pd was authorised for market use on 12 June, 2020.
Tivicay Pd is available in tablet, for suspension;oral dosage forms.
The generics of Tivicay Pd are possible to be released after 08 June, 2030.
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of TIVICAY PD before it's drug patent expiration?
More Information on Dosage
TIVICAY PD family patents
